New hope for tough cancers: experimental drug DPTX3186 enters first human trial

NCT ID NCT07312903

Recruiting now Disease control Sponsor: Dewpoint Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental oral drug called DPTX3186 in 40 adults with advanced solid tumors (like colorectal, gastric, lung, or triple-negative breast cancer) that are linked to a specific cell signal called Wnt. These participants have no other approved treatments left. The main goal is to check the drug's safety and how the body processes it, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DPTX3186 (an experimental oral drug)
What this could lead to: If it works, this could point toward a new treatment option for certain hard-to-treat cancers that have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 40 participants, so the main goal is safety, not effectiveness. Many drugs fail at this stage, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer gastric cancer lung cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

NEXT San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.